22:21 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

HP-3060 regulatory update

Hisamitsu said it submitted a regulatory application in Japan for HP-3060 to treat allergic rhinitis. The product is a systemic patch formulation of emedastine fumarate, a selective histamine H1 receptor (HRH1) antagonist, which uses Hisamitsu's...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

HP-3060: Phase II data

A Japanese Phase II trial in adults with allergic rhinitis showed that HP-3060 met the primary efficacy endpoint vs. placebo. No serious adverse reactions were reported. Hisamitsu could not be reached for details. Hisamitsu Pharmaceutical...
07:00 , Aug 5, 2013 |  BC Week In Review  |  Clinical News

HP-3060: Phase II started

Hisamitsu began a placebo-controlled Phase II trial to evaluate HP-3060 in adults with allergic rhinitis. Hisamitsu plans to start a Phase III trial of HP-3060 during its FY14 ending Feb. 28, 2014. Hisamitsu Pharmaceutical Co....